Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Y mAbs Therapeutics (YMAB)

Y mAbs Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:YMAB
DateTimeSourceHeadlineSymbolCompany
14/06/202402:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
14/06/202402:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
14/06/202402:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
13/06/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
12/06/202400:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
12/06/202400:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
10/06/202421:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
10/06/202421:44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/06/202412:05GlobeNewswire Inc.Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
05/06/202412:05GlobeNewswire Inc.Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202413:15GlobeNewswire Inc.Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202413:05GlobeNewswire Inc.Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202402:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202402:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
23/05/202423:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
21/05/202421:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202421:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:YMABY mAbs Therapeutics Inc
07/05/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202421:05GlobeNewswire Inc.Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
26/04/202412:05GlobeNewswire Inc.Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NASDAQ:YMABY mAbs Therapeutics Inc
25/04/202421:05GlobeNewswire Inc.Y-mAbs to Present at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
14/03/202413:05GlobeNewswire Inc.Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
07/03/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/03/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/03/202421:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/03/202421:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/03/202421:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/03/202400:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202412:30GlobeNewswire Inc.Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202411:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:YMAB

Your Recent History

Delayed Upgrade Clock